✦ LIBER ✦

Use of apoE genotyping as a pharmacogenetic biomarker in phase II disease modification trials for Alzheimer's disease

✍ Scribed by Stone, David J.; Molony, Cliona; Potter, William Z.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of FDG PET as an imaging biomarker i

✍ Herholz, Karl 📂 Article 📅 2012 🏛 Future Medicine 🌐 English ⚖ 530 KB

Contribution of APOE as a risk factor fo

✍ Thorlakur Jonsson; Erna Magnusdottir; Hildur R. Helgadottir; Hjorvar Petursson; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 193 KB

The Use of Apolipoprotein E Genotyping a

📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

A multicenter clinical trial to validate

✍ Cecchi, Marco; Berg, Sarah; Smith, Charles; Jicha, Gregory; Solomon, Paul; Sadow 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Biomarkers of fatty acid oxidation in a

✍ Quinn, Joseph; Shinto, Lynne; Yurko-Mauro, Karin; Galasko, Douglas; Aisen, Paul; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

A Pilot Experience in Genetic Counseling

✍ H. KARLINSKY; ODIE GEIGER; ANNE MACDOUGALL; MAURICE BLOCH; DESSA SADOVNICK; MICH 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB